CN111247150A - Fgfr抑制剂及其医药用途 - Google Patents
Fgfr抑制剂及其医药用途 Download PDFInfo
- Publication number
- CN111247150A CN111247150A CN201880052899.8A CN201880052899A CN111247150A CN 111247150 A CN111247150 A CN 111247150A CN 201880052899 A CN201880052899 A CN 201880052899A CN 111247150 A CN111247150 A CN 111247150A
- Authority
- CN
- China
- Prior art keywords
- compound
- pharmaceutically acceptable
- synthesis
- acceptable salt
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
本发明公开了一类FGFR抑制剂,及其在制备治疗与FGFR相关疾病的药物中的应用。具体公开了式(Ⅰ)所示化合物及其药学上可接受的盐。
Description
PCT国内申请,说明书已公开。
Claims (19)
- PCT国内申请,权利要求书已公开。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710698086 | 2017-08-15 | ||
CN2017106980863 | 2017-08-15 | ||
PCT/CN2018/100638 WO2019034076A1 (zh) | 2017-08-15 | 2018-08-15 | Fgfr抑制剂及其医药用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111247150A true CN111247150A (zh) | 2020-06-05 |
CN111247150B CN111247150B (zh) | 2022-11-08 |
Family
ID=65362616
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201880052899.8A Active CN111247150B (zh) | 2017-08-15 | 2018-08-15 | Fgfr抑制剂及其医药用途 |
Country Status (9)
Country | Link |
---|---|
US (1) | US11236094B2 (zh) |
EP (1) | EP3670513B1 (zh) |
JP (1) | JP7341122B2 (zh) |
KR (1) | KR20200041361A (zh) |
CN (1) | CN111247150B (zh) |
AU (1) | AU2018317153B2 (zh) |
CA (1) | CA3072979A1 (zh) |
RU (1) | RU2771311C2 (zh) |
WO (1) | WO2019034076A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114712365A (zh) * | 2022-06-07 | 2022-07-08 | 山东绿叶制药有限公司 | Trk抑制剂在制备治疗迟发性运动障碍药物中的应用 |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7341122B2 (ja) * | 2017-08-15 | 2023-09-08 | 石薬集団中奇制薬技術(石家庄)有限公司 | Fgfr阻害剤及びその医薬品の用途 |
WO2020164603A1 (zh) | 2019-02-15 | 2020-08-20 | 石药集团中奇制药技术(石家庄)有限公司 | 固体形式的fgfr抑制剂化合物及其制备方法 |
JP2022526713A (ja) | 2019-03-21 | 2022-05-26 | オンクセオ | がんの処置のための、キナーゼ阻害剤と組み合わせたDbait分子 |
EP4054579A1 (en) | 2019-11-08 | 2022-09-14 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
WO2021089005A1 (zh) * | 2019-11-08 | 2021-05-14 | 石药集团中奇制药技术(石家庄)有限公司 | 一种fgfr抑制剂的用途 |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
CN115433190A (zh) * | 2021-06-02 | 2022-12-06 | 药雅科技(上海)有限公司 | 不可逆杂环化合物fgfr抑制剂的制备方法和用途 |
WO2022166469A1 (zh) * | 2021-02-03 | 2022-08-11 | 药雅科技(上海)有限公司 | Fgfr激酶抑制剂及其应用 |
CN114853740B (zh) * | 2021-02-03 | 2023-08-01 | 药雅科技(上海)有限公司 | 炔类嘧啶化合物作为fgfr抑制剂的制备方法和用途 |
CN114057749B (zh) * | 2021-11-19 | 2023-12-22 | 药雅科技(上海)有限公司 | 不可逆炔类杂环化合物fgfr抑制剂的制备方法和用途 |
CN115141176B (zh) * | 2021-03-31 | 2023-08-22 | 药雅科技(上海)有限公司 | 炔代吲哚类fgfr抑制剂及其制备方法和用途 |
CN115215868A (zh) * | 2021-04-14 | 2022-10-21 | 药雅科技(上海)有限公司 | 杂环化合物fgfr抑制剂的制备方法和用途 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007056170A2 (en) * | 2005-11-02 | 2007-05-18 | Bayer Healthcare Ag | Pyrrolo[2,1-f] [1,2,4] triazin-4-ylamines igf-1r kinase inhibitors for the treatment of cancer and other hyperproliferative diseases |
WO2013087578A1 (en) * | 2011-12-15 | 2013-06-20 | Bayer Pharma Aktiengesellschaft | Disubstituted benzothienyl-pyrrolotriazines and their use as fgfr kinase inhibitors |
WO2013124316A1 (en) * | 2012-02-23 | 2013-08-29 | Bayer Intellectual Property Gmbh | Substituted benzothienyl-pyrrolotriazines and uses thereof |
CN104159900A (zh) * | 2011-12-15 | 2014-11-19 | 拜耳知识产权有限责任公司 | 取代的苯并噻吩基-吡咯并三嗪及其在癌症治疗中的用途 |
WO2016091849A2 (en) * | 2014-12-11 | 2016-06-16 | Bayer Pharma Aktiengesellschaft | Use of pan fgfr inhibitors and method of identifying patients with cancer eligible for treatment with a pan fgfr inhibitor |
WO2016142312A1 (en) * | 2015-03-09 | 2016-09-15 | Bayer Pharma Aktiengesellschaft | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline-containing combinations |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0512324D0 (en) | 2005-06-16 | 2005-07-27 | Novartis Ag | Organic compounds |
ATE507227T1 (de) * | 2005-11-17 | 2011-05-15 | Osi Pharm Inc | Kondensierte bicyclische mtor-inhibitoren |
EP2328872A1 (en) | 2008-06-19 | 2011-06-08 | AstraZeneca AB | Pyrazole compounds 436 |
EA026953B1 (ru) | 2012-02-28 | 2017-06-30 | Астеллас Фарма Инк. | Азотсодержащее ароматическое гетероциклическое соединение |
CN103450204B (zh) * | 2012-05-31 | 2016-08-17 | 中国科学院上海药物研究所 | 吡咯[2,1-f][1,2,4]并三嗪类化合物,其制备方法及用途 |
TW201536293A (zh) | 2013-07-18 | 2015-10-01 | Taiho Pharmaceutical Co Ltd | 對fgfr抑制劑具耐受性之癌的治療藥 |
JP7341122B2 (ja) * | 2017-08-15 | 2023-09-08 | 石薬集団中奇制薬技術(石家庄)有限公司 | Fgfr阻害剤及びその医薬品の用途 |
-
2018
- 2018-08-15 JP JP2020508589A patent/JP7341122B2/ja active Active
- 2018-08-15 CA CA3072979A patent/CA3072979A1/en active Pending
- 2018-08-15 RU RU2020110780A patent/RU2771311C2/ru active
- 2018-08-15 AU AU2018317153A patent/AU2018317153B2/en active Active
- 2018-08-15 US US16/639,442 patent/US11236094B2/en active Active
- 2018-08-15 WO PCT/CN2018/100638 patent/WO2019034076A1/zh unknown
- 2018-08-15 CN CN201880052899.8A patent/CN111247150B/zh active Active
- 2018-08-15 KR KR1020207007486A patent/KR20200041361A/ko not_active Application Discontinuation
- 2018-08-15 EP EP18846045.5A patent/EP3670513B1/en active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007056170A2 (en) * | 2005-11-02 | 2007-05-18 | Bayer Healthcare Ag | Pyrrolo[2,1-f] [1,2,4] triazin-4-ylamines igf-1r kinase inhibitors for the treatment of cancer and other hyperproliferative diseases |
WO2013087578A1 (en) * | 2011-12-15 | 2013-06-20 | Bayer Pharma Aktiengesellschaft | Disubstituted benzothienyl-pyrrolotriazines and their use as fgfr kinase inhibitors |
CN104159900A (zh) * | 2011-12-15 | 2014-11-19 | 拜耳知识产权有限责任公司 | 取代的苯并噻吩基-吡咯并三嗪及其在癌症治疗中的用途 |
WO2013124316A1 (en) * | 2012-02-23 | 2013-08-29 | Bayer Intellectual Property Gmbh | Substituted benzothienyl-pyrrolotriazines and uses thereof |
WO2016091849A2 (en) * | 2014-12-11 | 2016-06-16 | Bayer Pharma Aktiengesellschaft | Use of pan fgfr inhibitors and method of identifying patients with cancer eligible for treatment with a pan fgfr inhibitor |
WO2016142312A1 (en) * | 2015-03-09 | 2016-09-15 | Bayer Pharma Aktiengesellschaft | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline-containing combinations |
Non-Patent Citations (1)
Title |
---|
何丹丹 等: "具有EGFR/HER2双重抑制作用的小分子抑制剂的研究进展", 《中南药学》 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114712365A (zh) * | 2022-06-07 | 2022-07-08 | 山东绿叶制药有限公司 | Trk抑制剂在制备治疗迟发性运动障碍药物中的应用 |
Also Published As
Publication number | Publication date |
---|---|
WO2019034076A1 (zh) | 2019-02-21 |
US11236094B2 (en) | 2022-02-01 |
EP3670513A4 (en) | 2021-04-14 |
AU2018317153B2 (en) | 2021-12-23 |
RU2771311C2 (ru) | 2022-04-29 |
CN111247150B (zh) | 2022-11-08 |
JP2020532500A (ja) | 2020-11-12 |
US20200207773A1 (en) | 2020-07-02 |
RU2020110780A3 (zh) | 2021-09-16 |
CA3072979A1 (en) | 2019-02-21 |
KR20200041361A (ko) | 2020-04-21 |
JP7341122B2 (ja) | 2023-09-08 |
AU2018317153A1 (en) | 2020-03-05 |
RU2020110780A (ru) | 2021-09-16 |
EP3670513B1 (en) | 2023-09-20 |
EP3670513A1 (en) | 2020-06-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111247150B (zh) | Fgfr抑制剂及其医药用途 | |
JP6717457B2 (ja) | Wee1阻害剤としての1,2−ジヒドロ−3H−ピラゾロ[3,4−d]ピリミジン−3−オン誘導体 | |
EP3248980B1 (en) | Jak inhibitor | |
CN110139865B (zh) | Fgfr抑制剂 | |
JP7323603B2 (ja) | 三環式縮合フラン置換ピペリジンジオン系化合物 | |
CN110446712A (zh) | 作为A2A受体抑制剂的[1,2,4]三唑并[1,5-c]嘧啶衍生物 | |
JP7168149B2 (ja) | Fgfr阻害剤としてのピラジン-2(1h)-オン系化合物 | |
WO2019034075A1 (zh) | Fgfr和egfr抑制剂 | |
CN111542520B (zh) | 作为a2a受体抑制剂的并环类衍生物 | |
JP7123956B2 (ja) | スピロ化合物およびその使用 | |
CN111201225B (zh) | 作为mek抑制剂的类香豆素环类化合物及其应用 | |
AU2017359819B2 (en) | FGFR4 inhibitor and preparation method and use thereof | |
US10654868B2 (en) | Dihydropyrazole azepine compound serving as Akt inhibitor | |
CN109071469B (zh) | 三环类化合物及其应用 | |
CN111556869A (zh) | 作为csf-1r抑制剂的杂环化合物及其应用 | |
EP3766883B1 (en) | Imidaxopyrolone compound and application thereof | |
WO2007110649A2 (en) | Process for the preparation of 2,6,9-trisubstituted purines | |
WO2019001461A1 (zh) | Irak4抑制剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40028643 Country of ref document: HK |
|
GR01 | Patent grant | ||
GR01 | Patent grant |